Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company focused on developing chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. Its lead product candidate is rondecabtagene autoleucel (ronde-cel), an autologous dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma, currently in pivotal trials including the PiNACLE trial in the 3L+ setting and a Phase 1/2 trial in the 2L setting, as well as a Phase 3 head-to-head trial (PiNACLE-H2H) in the 2L setting. Another candidate is LYL273, a GCC-targeted CAR T-cell product enhanced with CD19 CAR expression and controlled cytokine release, in Phase 1 for refractory metastatic colorectal cancer. The company also employs approaches like c-Jun overexpression and NR4A3 gene knockout to combat T-cell exhaustion, and has platforms such as Epi-R and CD62L positive enrichment to improve T-cell function.

Lyell Immunopharma, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol LYEL. Its shares are traded in United States Dollars (USD). The company is headquartered in South San Francisco, California, and operates primarily in the United States.

Lyell Immunopharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage cell therapy company, it focuses on developing innovative CAR T-cell therapies for cancer, targeting both hematologic malignancies (such as large B-cell lymphoma) and solid tumors (such as metastatic colorectal cancer). The company's work involves genetic engineering of T-cells to enhance their ability to recognize and kill cancer cells while resisting exhaustion.

Lyell Immunopharma is headquartered in South San Francisco, California, United States. The company was incorporated in 2018 and primarily serves the U.S. market, as indicated by its listing on a U.S. exchange and its focus on clinical trials conducted in the United States. Its therapies are designed to address unmet medical needs in oncology, particularly for patients with relapsed or refractory large B-cell lymphoma and metastatic colorectal cancer.

Lyell Immunopharma is a clinical-stage biotechnology company that develops autologous CAR T-cell therapies, meaning each treatment is customized using a patient's own T-cells. The company's business model involves advancing its product candidates through clinical trials to obtain regulatory approval for commercialization. It generates value through its proprietary platforms, such as Epi-R, which creates stem-like T-cells with reduced exhaustion and improved antitumor activity, and CD62L positive enrichment to enhance CAR T-cell potency. Additionally, the company uses genetic modifications like c-Jun overexpression and NR4A3 gene knockout to make T-cells resistant to exhaustion, aiming to improve treatment outcomes for patients with hematologic cancers and solid tumors.